Comparative Pharmacology
Head-to-head clinical analysis: ALBAMYCIN versus ERYTHROCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBAMYCIN versus ERYTHROCIN STEARATE.
ALBAMYCIN vs ERYTHROCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albamycin (novobiocin) inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA supercoiling and replication.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
5-10 mg/kg intravenously every 8 hours. Maximum total daily dose: 30 mg/kg.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
None Documented
None Documented
3.5-4.5 hours in adults with normal renal function; prolonged to 20-40 hours in severe renal impairment, requiring dose adjustment.
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Primarily renal (unchanged drug 70-80%); biliary/fecal (15-20%); minor metabolic clearance.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic